Plain-English translation of NCT04288999 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 3 β Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Rectal cancer that returns after initial treatment is challenging to manage. This trial compares two treatment approaches: one group receives capecitabine () combined with radiation therapy before surgery, followed by additional after surgery; the other group goes straight to surgery followed by . The goal is to see which approach gives patients the best chance of preventing the cancer from coming back in the same area.
When rectal cancer returns in the pelvis after initial treatment, doctors need to know the best way to combine surgery and to give patients the longest time without cancer recurrence and the best survival outcomes. This trial will help answer that question.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You will be randomly assigned to one of two treatment groups. If assigned to the first group, you will receive pills and radiation therapy to the pelvis over several weeks, then undergo surgery, followed by additional . If assigned to the second group, you will have surgery first, then receive . Throughout treatment, you will have regular clinic visits, blood tests, and imaging scans to monitor your progress. The study will track you for several years to see how well each approach works and how it affects your quality of life.
AI-generated summary from trial data Β· Jun 18, 2026 Β· Not medical advice
Japan